Nasdaq 100 Stocks SEC Filings — March 17, 2026

RAD division secured order for 10 RIO Mini units with SARA licenses from major Midwest construction firm, signaling commercial traction in AI security tech

$1.3B SPAC merger with Enhanced Games advancing, inaugural Las Vegas event May 2026 with free tickets and medical program in Abu Dhabi, CEO highlights athlete health/compensation upside

Accelerate Arbitrage Fund discloses long position in shares/rights amid merger hype for PED-enabled sports disrupting traditional athletics

Received FDIC, CA DFPI, and Fed waiver approvals for USB merger, shareholder votes March 30, 2026, closing targeted Q2 2026

FY2025 revenue surged 2050% YoY to $23.6M driven by NTS acquisition, Q4 +2092% YoY to $6.1M, net loss improved 77% YoY to $2.0M

Q4 2025 Adjusted EBITDA turned positive at $5K (vs negative FY -$1.1M), operating cash flow +$0.1M vs -$1.5M YoY prior, zero long-term debt, $8.4M cash

Active $400K stock repurchase plan (76%/$301K executed on 151K shares as of Dec 31, 2025), total equity up to $18.2M from $11.9M YoY, over 10,000 devices managed

Q4 net loss improved 89% YoY to $0.6M and 41% QoQ, FY operating loss narrowed to $4.7M from $5.1M, positive cash from ops in Q4

Proxy seeks director election, auditor ratification, and exec comp approval at April 16, 2026 virtual AGM, 130M shares outstanding signals stable base

Completed NTS acquisition for $4M cash + 4M preferred shares (potential $5M earn-out), divested consumer apps for $1.35M cash, refocusing on IT/protection

Joint proxy available on SEC sites post-regulatory nods, de-risks previously announced merger with USB bank sub

Enhanced Games training at Abu Dhabi Earth complex with super suits and clinical PED program, targeting record-breaking and veteran athletes

FY2025 operating loss persisted at $4.7M (narrowed from $5.1M), FY Adjusted EBITDA negative $1.1M despite Q4 positivity, litigation expenses $0.7M

Q4 2025 revenue declined 1.7% QoQ from Q3 despite massive YoY surge, signaling potential momentum slowdown

Ongoing patent suit vs Cisco filed 2021 in TX court, plus historical costs weighing on margins

Potential shareholder rejection at March 30, 2026 votes, integration delays, dilution from new shares despite regulatory approvals

Merger execution risks including venue build (4 weeks from late April 2026), athlete participation uncertainty, PED stigma overhang

S-3 shelf registration filed March 17, 2026 incorporating 10-K, follows NTS preferred stock issuance, potential for future equity raises

$1M Newtek Bank revolver matures April 10, 2026 (zero drawn currently), repurchase plan expires May 8, 2026

Proxy proposes increasing authorized shares and ESPP reserves, potential dilution risk at April 16 AGM

NTS deal earn-out up to $5M contingent, unproven integration post divestitures

Closing Q2 2026 subject to final approvals and customary conditions post initial waivers

New RIO Mini order from major construction client validates AI tech demand, monitor for follow-on orders

$1.3B SPAC combo pre-May 2026 debut offers exposure to disruptive sports model with medical PEDs, free entry/musical acts to drive hype

Regulatory approvals de-risk deal, shareholder votes March 30 position for Q2 close, joint proxy details terms

2050% YoY revenue to $23.6M, losses -77%, positive Q4 EBITDA/cash flow, $8.4M cash/no debt for growth in managed IT ($14.8M FY)

76% of $400K buyback executed, zero debt, $18.2M equity supports reinvestment in 10K+ devices

April 16 virtual meeting to approve share increases/ESPP, potential for biotech expansion if passed

FY breakdown shows Managed IT dominance at $14.8M (63%), Procurement $5.4M scaling post-acquisition

Targeting prime record-breakers and mid-30s veterans with Abu Dhabi facilities, addresses Olympics compensation gap

Ended 2025 with $8.4M cash (up via ops), supports patent litigation and growth sans dilution immediacy

Merger with USB enhances California footprint post-FDIC/DFPI nods

IPM's 2050% YoY revenue surge to $23.6M post-NTS acq contrasts AParadise $1.3B SPAC and CWBC merger; 3/8 filings show acquisition-driven scale, implying sector reliance on deals for growth but integration risks

IPM Q4 EBITDA +$5K/positive cash flow but FY losses $4.7M ops/$2.0M net (improved 77% YoY), AITX order positive sans financials; highlights post-acq margin pressure averaging ~ongoing losses despite rev explosion

3/8 filings cluster events - CWBC-USB votes March 30, Altimmune AGM April 16; de-risking mergers/governance, potential volatility/alpha from approvals

IPM's $301K buyback (76% of $400K), zero LT debt, $8.4M cash vs revolver maturity; no dividends noted across filings, favors repurchases/reinvestment in growth sectors

Enhanced Games May debut, CWBC close Q2, IPM loan/buyback expirations April-May; builds catalyst calendar for sports/IT/banking subsectors

IPM S-3 amid strong rev but losses flags equity access need; Altimmune share increase proposal, common in growth cos but watch for overhang vs peers

Shareholder approval meetings March 30, 2026; monitor votes for Q2 close risks [March 30, 2026]

Virtual meeting April 16, 2026 for share increases, director elections, comp vote; dilution/approval outcomes [April 16, 2026]

$1M facility matures April 10, 2026 (zero drawn); renewal/refinance impact on cash [April 10, 2026]

Expires May 8, 2026 after $301K spent; remaining execution or extension signal [May 8, 2026]

Las Vegas groundbreaking late April 2026, inaugural event May 2026; construction/athlete signup progress [May 2026]

Ongoing since July 2021; settlement or ruling updates post-10-K incorporation [Ongoing]

Midwest construction RIO Mini deployment; revenue recognition or expansion news [Short-term]

Post-Q4 QoQ dip (-1.7% rev), watch sequential growth in managed IT/subscriptions [Next quarter]